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Abstract
Background: The effect of ethnicity on the prevalence and management of hypertension and associated chronic
kidney (CKD) disease in the UK is unknown.
Methods: We performed a cross sectional study of 49,203 adults with hypertension to establish the prevalence
and management of hypertension and associated CKD by ethnicity. Routinely collected data from general practice
hypertension registers in 148 practices in London between 1/1/07 and 31/3/08 were analysed.
Results: The crude prevalence of hypertension was 9.5%, and by ethnicity was 8.2% for White, 11.3% for South
Asian and 11.1% for Black groups. The prevalence of CKD stages 3-5 among those with hypertension was 22%.
Stage 3 CKD was less prevalent in South Asian groups (OR 0.77, 95% CI 0.67 - 0.88) compared to Whites (reference
population) with Black groups having similar rates to Whites. The prevalence of severe CKD (stages 4-5) was higher
in the South Asian group (OR 1.53, 95% CI 1.17 - 2.0) compared to Whites, but did not differ between Black and
White groups. In the whole hypertension cohort, achievement of target blood pressure (< 140/90 mmHg) was
better in South Asian (OR 1.43, 95% CI 1.28 - 1.60) and worse in Black groups (OR 0.79, 95% CI 0.74 - 0.84)
compared to White patients. Hypertensive medication was prescribed unequally among ethnic groups for any
degree of blood pressure control.
Conclusions: Significant variations exist in the prevalence of hypertension and associated CKD and its
management between the major ethnic groups. Among those with CKD less than 50% were treated to a target BP
of ≤ 130/80 mmHg. Rates of ACE-I/ARB prescribing for those with CKD were less than optimal, with the lowest
rates (58.5%) among Black groups.
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Background
Hypertension is a major risk factor for cardiovascular
disease (CVD) and for progression of chronic kidney
disease (CKD) towards end stage kidney disease (ESKD)
[1,2]. The public health burden of CKD and ESKD is a
matter of national priority in the UK [3] and is the sub-
ject of recently published national CKD guidelines [4].
The seventh report from the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) and the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(NKF KDOQI) [1,5] have identified patients with CKD
as a high risk group in which blood pressure control is
particularly important. Studies in the USA have identi-
fied that blood pressure control in CKD is poor and
that risk factors for poor blood pressure control in
patients with CKD include non-Hispanic Black ethnicity,
albuminuria and age > 75 [6]. Similarly in the UK it is
of concern that a higher proportion of the prevalent
renal replacement population comes from ethnic minor-
ity groups compared to the UK Caucasian population
(17.8% vs 11%) [7].
The introduction of performance related pay for gen-
eral practice, the quality and outcomes framework
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in hypertension control in the UK, and there is also evi-
dence that inequalities in performance between affluent
and deprived areas have diminished [9,10]. However
there remains room for improvement, especially in high
risk groups such as individuals with CKD [11].
In the UK, the effect of ethnicity on blood pressure
control and associated CKD in a hypertensive popula-
tion is not known. Previous studies of primary care
hypertension management in the UK have excluded or
had very low numbers of patients with CKD [9,11] or
have had small ethnic minority populations [11,12].
Millet et al [9,13] have demonstrated disparities by eth-
nicity in blood pressure control in a London study, but
had low reporting rates of CKD.
This study uses data from a large, multi-ethnic popu-
lation with hypertension and high recorded levels of self
reported ethnicity. We have excluded patients with a
diagnosis of diabetes mellitus, as this group has pre-
viously been the subject of a related study [14]. Our aim
is to examine the effect of ethnicity on the prevalence
and management of hypertension, and on the prevalence
and severity of associated CKD.
Methods
The study was set in the three geographically contiguous
east London Primary Care Trusts (PCTs) of Newham,
Tower Hamlets and City & Hackney, with a combined
GP registered population of 829,710 in mid 2008. In the
2001 UK census 51.3% of the population in these three
P C T sw a sr e c o r d e da so fn o n - W h i t ee t h n i co r i g i n[ 1 5 ]
(see Additional File 1: Table S1/S2 for complete demo-
graphic breakdown). The populations of these PCTs are
among the eight most socially deprived localities in Brit-
ain [15]. 148 of the 151 general practices contributed
data as part of a regular annual audit of chronic disease
management, which forms part of a primary care
chronic disease management programme [16]. Practice
data covered more than 98% of the GP registered popu-
lation in the three PCTs. All data was fully anonymised,
and managed according to UK NHS information gov-
ernance requirements. Ethics approval was not required
for this observational study.
Clinical data collection
Practice computer databases were interrogated using
Morbidity Information Query and Export Syntax
(MIQUEST) software which has been validated as an
accurate and appropriate method for data extraction of
patients with CKD in general practice [17]. All adult
patients with a computerised diagnostic Read code for
hypertension were included. Read codes are the clinical
classification system used in UK general practice to
identify patients with a specific chronic disease [18].
Variables included in the analysis were recorded in the
period 1/1/07 and 31/3/08. While patients may have
had multiple clinic visits during this period, only the lat-
est data point within the study period was used for ana-
lysis. Variables for analysis included renal function as
the estimated glomerular filtration rate (eGFR)
expressed by the 4 variable MDRD equation [19], systo-
lic and diastolic blood pressure, total cholesterol, smok-
ing status, diagnosis of ischaemic heart disease, and
prescription data for the use of antihypertensive medica-
tions (angiotensin converting enzyme inhibitor (ACE-I),
angiotensin receptor blocker (ARB), thiazide diuretics,
calcium channel blockers, beta blockers and alpha
blockers). Blood pressure was measured using both
manual and automated devices during routine clinical
consultations. Data entry to the hypertension register
occurs during the consultation.
Isolated systolic hypertension (ISH) is defined as stage
1 ≥ 140 and ≤ 90 mmHg and stage 2 as ≥ 160/≤ 90
mmHg. Renal function is expressed as stage of chronic
kidney disease defined by current UK guidelines [19]
based on the eGFR value: stage 3a CKD (eGFR 45-59
ml/min/1.73 m
2), stage 3b CKD (eGFR 30-44 ml/min/
1.73 m
2), stage 4 CKD (eGFR 15-29 ml/min/1.73 m
2)
and stage 5 CKD (eGFR < 15 ml/min/1.73 m
2). All
eGFR measures have been corrected for Black ethnicity
(multiply eGFR by 1.21). Different methods for measur-
ing the serum creatinine (from which the eGFR is calcu-
lated) are used in the study area, however, as we report
elsewhere [14], differences between techniques result in
very small changes in eGFR which are likely to be
equally distributed across the different ethnic groups
and we do not consider that these differences will
change the overall classification of CKD.
During the study period, of the 75,103 adults coded
with hypertension, 92.4% had ethnicity recorded. We
excluded the 28% with a diagnosis of diabetes (see Addi-
tional File 1: Table S3/S4 for analysis with diabetic cases
included), leaving 49,203 cases with hypertension for
analysis. An eGFR (recorded in the fifteen month study
period) was available for analysis in 57.1% of cases. The
proportion of cases with an eGFR measure varied by
ethnic group (White 62%, South Asian 54.6%, Black
52.3%, Chi
2 p < 0.001). A blood pressure reading was
recorded for 92%, total cholesterol for 73%, and smoking
status for 80.7%. Due to low levels of recorded protei-
nuria (5%) and body mass index (BMI) (15%) during the
study we excluded these variables from the analysis.
Ethnicity data
Self reported ethnicity was recorded at the practice dur-
ing registration or routine consultation [14]. Ethnic cate-
gories are based on the UK 2001 census and for this
study were condensed into five categories: White
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Caribbean, Black British, other Black and mixed Black),
South Asian (Bangladeshi, Pakistani, Indian, Sri Lankan,
British Asian, other South Asian or mixed Asian), Other
(Chinese, Other ethnic groups, other mixed groups),
and unknown. Missing or incomplete data was recorded
as unknown (see Additional File 1: Table S1 for full
details of UK 2001 Census ethnic groups).
To calculate the prevalence of hypertension in each
ethnic group in the study area, we used the Greater
London Authority (GLA) mid-year 2006 age banded
population estimates by ethnic group [20]. The GLA
provides estimates of ethnicp o p u l a t i o n sb ya g eb a n d ,
which are adjusted from the Office of National Statistics
(ONS) midyear estimates. Although the ONS data are
considered accurate for London overall, they conceal
under counting for some inner London boroughs such
as Newham. The GLA produce a ‘high’ and ‘low’ popu-
lation estimates, both estimates produced similar hyper-
tensive prevalence figures, our report uses the low
estimate as population denominator.
Statistical analysis
All statistical analyses used Stata version 10 [21]. Differ-
ences in the prevalence of CKD between ethnic groups
are expressed as odds ratios with White ethnicity con-
sidered as neutral risk (odds ratio = 1). Age and sex
adjusted odds ratios for CKD prevalence were adjusted
by key risk factors (mean systolic blood pressure, mean
total cholesterol, smoking status and IHD diagnosis) and
clustered by GP practice. Blood pressure control is
expressed as a percentage of those meeting previously
defined values for either poor or optimal control in each
group. Categorical variables were assessed for differences
by using a Chi squared test, continuous numerical vari-
ables using Anova.
Results
In this cohort 45.3% were males, the average age for
males was 59.7, and for females was 62.4 years. The
crude prevalence of hypertension among adults in east
London was 9.5% and by ethnic group was 8.2% for
White, 11.3% for South Asian and 11.1% for Black
groups. East London has a very young population, the
crude population prevalence rises to 14.8% when age
standardized to the European standard population. The
prevalence of hypertension by age and ethnicity was
examined (removing those with diagnosed diabetes mel-
litus), using practice data as numerator, and the midyear
population estimates from the Greater London Author-
ity as denominator. Figure 1 illustrates the trend
towards earlier onset and higher prevalence of hyperten-
sion among ethnic minority groups, with the South
Asian groups having the highest prevalence of hyperten-
sion among all age groups.
The crude prevalence of CKD (eGFR < 60 ml/min/
1.73 m
2) among the hypertensive population was 22%.
The prevalence of CKD risk factors by ethnicity and
gender was examined. The White group had a higher
mean age and smoking rates than other groups (p <
0.001). Black groups had the lowest rates of recorded
ischaemic heart disease (p < 0.001). The distribution of
risk factors for CKD by ethnicity, and the prevalence of
CKD among all those with an eGFR value are shown in
tables 1 and 2.
Using logistic regression we first examined the preva-
lence of stage 3 CKD (eGFR 30-59 ml/min/1.73 m
2)b y
ethnicity among all hypertensives, adjusted for age and
sex and clustered by practice. Compared to the White
population the South Asian population had a signifi-
cantly lower overall prevalence of CKD stage 3 (OR
0.77, 95% CI: 0.67-0.88) and this difference remains with
further adjustment for systolic blood pressure, total cho-
lesterol, smoking status and diagnosis of ischaemic heart
disease (see Table 3).
We then examined the risks of having severe CKD
(stages 4 and 5, eGFR < 30 ml/min/1.73 m
2), by con-
ducting a further analysis restricted to cases with an
eGFR < 60 ml/min/1.73 m
2 to determine if ethnicity is
marker for disease severity in established cases of CKD.
This showed that South Asian groups had a significantly
greater risk of severe CKD (stages 4-5, eGFR < 30 ml/
min/1.73 m
2) compared to the White population (OR
1.53, 95% CI: 1.17-2.0 with adjustment for risk factors)
(see Table 4).
T a b l e5s h o w sb l o o dp r e s s u r ec o n t r o lb ye t h n i cg r o u p ,
comparing control among hypertensive patients with
eGFR values above and below 60 ml/min/1.73 m
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Figure 1 Prevalence of essential Hypertension by age and
aggregated ethnic groups, using low east London GLA
population estimates as denominator. Values are population
percentages (95% CIs).
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140/90 mmHg. Those with Black ethnicity had worse
blood pressure control compared to other groups, regard-
less of CKD status. South Asian groups achieved the best
blood pressure control. This was confirmed by further
analysis to examine the effect of ethnicity on the achieve-
ment of controlled blood pressure (< 140 and < 90
mmHg) regardless of CKD status, adjusted by age and sex
and clustered by practice. Achievement of target blood
pressure control was better in South Asian (OR 1.43, 95%
CI 1.28 to 1.60) and worse in Black groups (OR 0.79, 95%
CI 0.74 to 0.84) compared to the White population.
The mean number of prescribed medications for
hypertension for those without CKD was 1.83, and for
those with CKD was 2.17. Among those with CKD less
than 50% were treated to a target BP of ≤ 130/80
mmHg. A higher proportion of South Asian patients
(42.7%) achieved this target than other ethnic groups.
Among this hypertensive population only 3.2% had stage
2 ISH (SBP > 160 and DBP < 90 mmHg).
Table 6 shows prescribing rates stratified by blood
pressure control. There are marked differences in
prescribing by ethnicity, with lower rates of ACE-I/ARB
prescribing for Black groups, but higher rates of calcium
channel blocker and thiazide diuretic use in this popula-
tion, commensurate with current guidelines [22]. Black
groups are prescribed more medications at all levels of
blood pressure control.
Table 7 shows prescribing stratified by eGFR level.
This shows that patients with CKD were prescribed a
higher mean number of antihypertensive drugs.
Approximately 60% of hypertensive patients with CKD
were prescribed ACE-I/ARB medications.
Discussion
This study is the first of its kind to examine the associa-
tion of ethnicity, hypertension and CKD in a UK popu-
lation. Using routine clinical data from a socially
deprived multiethnic population with uniquely high
levels of self reported ethnicity, we examine variation in
prevalence and management of hypertension and asso-
ciated CKD. The exclusion of patients with diabetes
mellitus, which has much higher rates among the South
Asian population, allows us to evaluate the effect of
Table 1 Prevalence of CKD risk factors among all hypertensives by ethnicity and gender (excluding those with
diabetes mellitus)
No. of individuals Mean
age (years)
SBP
Mean (SD)
mmHg
DBP
Mean (SD)
mmHg
Total cholesterol Mean (SD)
mmol/L
% with IHD diagnosis % smoking
White 22 489 65.2 136.5 (16.5) 79.1 (10.6) 4.9 (1.1) 13.8 24.2
South Asian 9 757 57.4 132.6 (16.7) 79.7 (10.4) 4.7 (1.1) 11.6 14.2
Black 12 717 57.0 138.3 (16.9) 83.0 (11.0) 4.9 (1.0) 5.1 12.7
Other 3 776 62.0 136.3 (16.5) 80.3 (10.8) 5.0 (1.1) 12.6 17.5
p † = < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Female 27 018 62.4 135.9 (16.7) 79.9 (10.5) 5.0 (1.1) 8.0 17.1
Male 22 185 59.9 137 (17.0) 81.1 (11.2) 4.7 (1.1) 13.8 21.6
* Abbreviations: SBP - systolic blood pressure, DBP diastolic blood pressure, IHD - ischaemic heart disease
† - p value for difference between groups (ANOVA)
Table 2 Prevalence of CKD stages 3-5 among hypertension cases with eGFR values (ml/min/1.73 m
2), by ethnicity and
gender (excluding those with diabetes mellitus)
Hypertensives with eGFR measured (n)
*†
eGFR >
60
CKD 3a eGFR 45-
60
CKD 3b
eGFR 30-
45
CKD 4 eGFR 15-
30
CKD 5 eGFR <
15
White 13 953 75.6% 16.7% 6.2% 1.3% 0.2%
South
Asian
5 324 85.6% 9.8% 2.9% 1.1% 0.6%
Black 6 731 81.8% 14.3% 2.8% 0.7% 0.5%
Other 1 859 80.7% 13.0% 4.9% 1.2% 0.2%
Female 16 267 76.5% 16.5% 5.3% 1.1% 0.3%
Male 13 482 82.5% 12.0% 3.9% 1.1% 0.5%
* eGFR (ml/min/1.73 m
2) recorded in the preceding 15 months
†The proportion of cases with a valid eGFR varied by ethnic group (White 62%, South Asian 54.6%, Black 52.3%, p < 0.001).
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Table S3/S4 for an analysis including diabetic patients).
Our results illustrate the earlier onset and higher preva-
lence of hypertension among South Asian and Black
groups compared to the White population in the UK. In
our cohort the prevalence of CKD stages 3-5 was 22%.
This is higher than the 18% prevalence of CKD identi-
fied in a diabetic cohort in the same area of the UK,
suggesting that hypertension may be an equally powerful
risk factor for the development of CKD as diabetes mel-
litus [14]. White groups were associated with a higher
prevalence of milder CKD (stage 3) (see table 3). In
common with our findings for diabetic patients, severe
CKD (stages 4,5) is significantly more prevalent among
South Asian groups, even after adjustment for age and
key clinical indicators.
Blood pressure control in the UK has shown steady
improvement over time [11]. Pay for performance
schemes, such as the QOF, contribute to this, with evi-
dence suggesting that quality of care for conditions tar-
geted in the UK QOF improve, albeit with a ceiling
effect [23]. In this cohort over 80% had BP values =<
140/90 mmHg, which compares favourably with 2006
data from the Health survey for England which reported
52% control to < 140/90 mmHg among those with trea-
ted hypertension. We found significant differences by
ethnicity in achieving this target, with lower rates
among Black groups. High systolic blood pressure is a
key determinant of CKD progression [24] and the bene-
fits of treatment for systolic blood pressure have been
clearly established [25-27]. Access to primary and sec-
ondary care is free at the point of need in the UK NHS
and free prescriptions are available for the poorest
groups, hence differential access to care in this popula-
tion is unlikely to account for the observed differences
between groups.
In patients with an eGFR < 60 ml/min/1.73 m
2,a
recommended blood pressure of < 130/80 mmHg [1]
was achieved in less than 50% of patients in all ethnic
groups and less than 30% in Black groups. These find-
i n g sa r ec o m p a r a b l ew i t hap r e v i o u ss t u d yo fd i a b e t i c
patients with CKD in east London, and a study of
patients with CKD in the USA [6,14]. The renoprotec-
tive benefits of ACE-I and ARB’s are well established
[28-30] and current UK CKD guidelines advocate the
use of these drugs in patients with CKD [4]. However
nearly 40% of patients with CKD in this study did not
receive an ACE-I or ARB, and Black patients were sig-
nificantly less likely to be prescribed these medications
than other ethnic groups in contrast to the findings of
the recent AASK study which demonstrates the benefits
of these medications in this patient group [28].
We found that achievement of target blood pressure to
< 140/90 mmHg was superior in patients with an eGFR <
60 ml/min/1.73 m
2 compared to those with a eGFR > 60
ml/min/1.73 m
2 . Previous studies have demonstrated
improved blood pressure control in the presence of two
or more comorbidities compared to hypertension alone
[9,13]. This suggests that clinicians may adopt a more
aggressive approach to blood pressure control if patients
are identified as “higher risk” due to other cardiovascular
comorbidities. Furthermore, the presence of these
comorbidities may influence prescribing decisions which
contribute to blood pressure control.
Our finding that South Asian patients have higher rates
of more severe CKD, in spite of better blood pressure
Table 3 Ethnicity and the prevalence of CKD stage 3 (eGFR 30-59 ml/min/1.73 m
2) among hypertensive patients
Ethnic
group
No. hypertensive No. hypertensive with CKD 3 only CKD stage 3* Odds Ratio
(95% CI)
CKD stage 3 † Odds Ratio (95% CI)
White 13 953 3 193 1 1
South Asian 5 324 681 0.77 (0.67-0.88) 0.75 (0.64-0.88)
Black 6 731 1 147 1.13 (1.01-1.28) 1.09 (0.95-1.25)
Other 1 859 333 0.85 (0.74-0.98) 0.78 (0.68-0.90)
*adjusted by age and sex and clustered by GP practice
† additional adjustment by systolic blood pressure, total cholesterol, smoking status and diagnosis of IHD
Table 4 Ethnicity and the prevalence of CKD stage 4 and 5 among hypertensives with an eGFR < 60 ml/min/1.73 m
2
Ethnic
group
No. hypertensive No. hypertensive with CKD 4 and 5 CKD stages 4,5*
OR (95% CI)
CKD stages 4,5 †
OR (95% CI)
White 3 407 214 1 1
South Asian 767 86 1.53 (1.17, 2.0) 1.44 (1.00, 1.85)
Black 1 223 76 0.80 (0.60, 1.06) 0.87 (0.62, 1.22)
Other 359 26 1.10 (0.77, 1.58) 1.12 (0.75, 1.47)
*adjusted by age and sex and clustered by GP practice
† additional adjustment by systolic blood pressure, total cholesterol, smoking status and diagnosis of IHD
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particularly given that the lower mean blood pressure in
this group would be expected to result in a lower preva-
lence of severe renal disease. There are several potential
explanations for this finding, one being that hypertension
affects South Asians at a younger age than other ethnici-
ties, and the longer duration of disease may lead to more
severe complications such as advanced CKD.
Recently the MYH 9 gene has been identified as a
marker for more rapid progression to ESKD in Black
patients [31,32] due to non-diabetic kidney disease and
it is possible that a similar genetic predisposition to
more rapid progression even in the face of a relatively
low blood pressure exists in the South Asian population
but this hypothesis requires further study. An additional
explanation for the observed higher prevalence of severe
CKD in South Asians may in part be due to more rapid
progression of CKD in the South Asian population,
combined with increased length of survival in this
group. A prospective study examining progression of
CKD between different ethnic groups is currently under-
way to address this issue.
Table 5 Blood pressure control among hypertensives with and without CKD, by ethnicity
Ethnic group No. of
hypertensives
% with BP > 140 and > 90
mmHg
% with BP ≤130 and ≤80
mmHg
Mean no of anti-hypertensive
drugs
All hypertensives
White 21 113 11.9 28.9 1.78
South Asian 8 839 12.2 37.5 1.62
Black 11 791 20.4 24.2 1.95
Chi squared test, p = < 0.001 < 0.001 < 0.001
eGFR > 60 ml/min/1.73
m
2
White 10 353 11.7 27.2 1.81
South Asian 4 469 11.9 35.9 1.64
Black 5 418 19.5 23.8 2.04
Chi squared test, p = < 0.001 < 0.001 < 0.001
eGFR < 60 ml/min/1.73
m
2
White 3 365 6.63 34.1 2.16
South Asian 756 8.07 42.7 2.00
Black 1 202 14.3 28.2 2.38
Chi squared test, p = < 0.001 < 0.001 < 0.001
Table 6 Prescribing rates by ethnicity, stratified by BP control
No. of
hypertensives
Mean Blood pressure
mmHg (SD)
% ACE/
ARB
%
CCB
%
Thiazides
%
Beta-
blockers
%
Alpha
blockers
Mean no. of
drugs
BP > 140 and
>9 0m mH g
White 6 567 152.4 (13.1) 54.6 54.2 45.7 28.6 12.6 1.95
South Asian 8 839 152.4 (13.9) 52.2 54.6 37.5 27.5 9.5 1.81
Black 11 791 153.6 (14) 45.7 74.5 51.1 23.3 17.9 2.13
ANOVA p value < 0.01 <
0.01
< 0.01 < 0.01 < 0.01 < 0.01
BP < 130 and < 80
mmHg
White 6 110 128.2 (14.2) 52.7 46.2 38.1 31.6 9.4 1.78
South Asian 3 318 125.8 (14) 48.6 47.0 30.0 27.7 7.3 1.60
Black 2 855 129.8 (14) 39.2 64.5 49.8 25.6 11.6 1.90
ANOVA p value < 0.01 <
0.01
< 0.01 < 0.01 < 0.01 < 0.01
* ACE-I - angiotensin converting enzyme inhibitor, ARB - angiotensin receptor blocker, CCB - calcium channel blocker
Hull et al. BMC Nephrology 2011, 12:41
http://www.biomedcentral.com/1471-2369/12/41
Page 6 of 9Geographic variations in cardiovascular mortality at a
similar blood pressure level are well documented [33].
The uniform blood pressure targets recommended by
hypertension guidelines may paradoxically disadvantage
some ethnic groups in which the normal mean blood
pressure is lower than in other groups. For example if
the normal mean blood pressure of South Asians is
l o w e rt h a nf o rB l a c ko rW h i t eg r o u p s ,a“o n es i z ef i t s
all” blood pressure target may be too high to allow opti-
mal renal protection in South Asian patients.
The strengths of this study include the size of the
study population which includes over 50% of patients
from ethnic minorities. Our population is likely to be
representative of other multiethnic, low income, urban
areas in the UK, hence our findings should be generali-
sable, and of interest to clinicians and health service
commissioners. The exclusion of patients with diabetes
highlights the higher than expected prevalence of CKD
in this patient group with hypertension alone.
The limitations of this study are linked to the prag-
matic nature of this primary care database. The entry
criteria for a diagnosis of hypertension depends on deci-
sions made in a routine clinical setting, and we use only
the latest BP data point for each case for analysis. Simi-
larly the accuracy of comorbid diagnoses, and the com-
pleteness of clinical measurements will be subject to
routine clinical variation. eGFR values were available for
57% of cases and there was significant variation by eth-
n i cg r o u p .W er e c o g n i s et h a t this may introduce bias.
Within the UK health system there are no structural
barriers to healthcare, hence differential access to care is
unlikely. We are aware that combining sub groups
within the South Asian and Black populations may
mask important differences in behavior and health
beliefs between population groups which in turn may
contribute to health outcomes.
We did not have access to individual drug dosing
regimes, and so cannot comment on the intensity of
hypertension treatment [34] or on whether possible
therapeutic inertia by clinicians varied by ethnicity or
CKD status. The collection and quantification of protei-
nuria data in primary care remains suboptimal for
hypertension, hence this important variable could not be
included in the analysis, eGFR recording is also lower
than optimal in this cohort. Neither eGFR nor protei-
nuria were included as UK QOF indicators for hyperten-
sion at the time of data collection which may explain
low levels of recording. A cross sectional study such as
this cannot take account of deaths and other movement
in and out of the cohort, which may affect our overall
estimates of the burden of CKD.
Questions also remain about the validation and use of
adjustments of the MDRD generated eGFR by ethnicity.
Despite these concerns, it is currently in universal use
to classify CKD and monitor progression of renal dis-
ease. Until more refined equations enter the main-
stream, it remains the best tool available to us.
The data from this large cross sectional study identi-
fies differences by ethnicity in the prevalence of hyper-
tension and associated CKD, and in the achievement of
blood pressure control and drug prescribing. These dis-
parities in hypertension management have persisted in
spite of steady improvements in primary care hyperten-
sion management in the UK.
Potential strategies to reduce the observed disparities
include improved awareness by clinicians, and the
Table 7 Prescribing rates by ethnicity, stratified by eGFR level
No. of
hypertensives
Mean blood pressure mmHg
(SD)
%
ACE/
ARB
%
CCB
%
Thiazides
%
Beta-
blockers
%
Alpha
blockers
Mean
no.
of
drugs
eGFR > 60 ml/min/1.73
m
2
White 10 546 136.5 (15.5) 54.3 48.1 41.9 27.1 9.8 1.81
South Asian 4 557 132.4 (16.1) 51.5 47.1 32.5 25.5 7.6 1.64
Black 5 508 138.2 (16.1) 43.2 71.4 53.0 22.0 14.7 2.04
ANOVA p value < 0.01 < 0.01 <
0.01
< 0.01 < 0.01 < 0.01 < 0.01
eGFR < 60 ml/min/1.73
m
2
White 3 407 136.1 (17.4) 64.2 56.3 35.7 16.2 43.5 2.16
South Asian 767 134.3 (18.8) 60.3 56.7 32.7 12.4 37.4 2.00
Black 1 223 138.9 (18.4) 58.5 72.9 30.3 22.7 53.7 2.38
ANOVA p value < 0.01 < 0.01 <
0.01
< 0.01 < 0.01 < 0.01 < 0.01
* Abbreviations: ACE-I - angiotensin converting enzyme inhibitor, ARB - angiotensin receptor blocker, CCB - calcium channel blocker
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Page 7 of 9public, of the excess risk associated with certain ethnic
groups, and a greater use of ACE-I/ARB and diuretics
to improve blood pressure control and reduce progres-
sion of kidney disease. The inclusion of annual measures
of eGFR, BMI and proteinuria, potentially modifiable
risk factors for cardiovascular and progressive renal dis-
ease [29,35,36], in the hypertension domain of the UK
QOF offers an opportunity to monitor renal function
and intervene at an early stage.
Conclusions
Additional studies need to identify whether target blood
pressure for the prevention of CKD progression should
to be tailored by reference to ethnicity. Whereas this
strategy may have merit at a biological level, any benefit
must be measured against the risk of increasing the
complexity of blood pressure guidelines. Improving cur-
rent practice to reach national standards should be the
focus of attention while prospective studies are con-
ducted to address some of the unanswered questions.
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management of hypertension and associated chronic kidney
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